Previous 10 | Next 10 |
2024-04-11 05:20:56 ET Read the full article on Seeking Alpha For further details see: AstraZeneca to boost annual dividend by 7%
2024-04-10 12:50:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...
2024-04-10 05:49:03 ET Roche ( OTCQX:RHHBY ) has obtained CE Mark for its pre-diluted VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx test.... Read the full article on Seeking Alpha For further details see: Roche companion diagnostic test wins CE Mark to i...
2024-04-09 14:53:06 ET More on STOXX Europe 600 Index: U.S. Employment Data To Set Dollar's Course Greenback Losses Extended, But Look For Consolidation In North America Rate Adjustment Underpins Greenback JPMorgan’s top European picks European...
2024-04-09 12:55:31 ET More on STOXX Europe 600 Index: U.S. Employment Data To Set Dollar's Course Greenback Losses Extended, But Look For Consolidation In North America Rate Adjustment Underpins Greenback European losers of higher financing costs - JPMorgan ...
2024-04-09 08:54:46 ET More on Vincerx Pharma Vincerx Pharma GAAP EPS of -$0.23 beats by $0.06 Seeking Alpha’s Quant Rating on Vincerx Pharma Historical earnings data for Vincerx Pharma Financial information for Vincerx Pharma Read the full a...
2024-04-06 06:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The market’s ri...
Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications with the latest in HER2 expressing (IHC 3+) metastatic cancers Daiichi Sankyo (TSE: 4...
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s ENHERTU which showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers AstraZ...
2024-04-05 16:14:43 ET More on AstraZeneca, Daiichi Sankyo What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca Imfinzi im...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
2024-06-29 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with chemotherapy demonstrated a statistically sign...
2024-06-20 08:46:01 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for...